Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18324930 | 0.99 | PTGS2 (0.33) | PTGS2PTGS1KDM4EGAAMAPT | |
| SCHEMBL18324935 | 0.95 | PTGS2 (0.34) | PTGS2PTGS1NISCH | |
| SCHEMBL18324928 | 0.93 | CYP11B1 (0.33) | PTGS2PTGS1KDM4EGAAMAPT | |
| SCHEMBL18324924 | 0.92 | AKR1C3 (0.37) | PTGS2PTGS1 | |
| SCHEMBL18324927 | 0.91 | CYP11B1 (0.35) | PTGS2PTGS1KDM4EGAAMAPT | |
| SCHEMBL21374095 | 0.89 | PTGS2 (0.36) | PTGS2PTGS1 | |
| SCHEMBL18324939 | 0.88 | KDM4E (0.34) | PTGS2KDM4EGAAMAPTMAPK1 | |
| SCHEMBL18324929 | 0.88 | PTGS2 (0.32) | PTGS2PTGS1CYP11B1CYP11B2RXRA | |
| SCHEMBL18324942 | 0.87 | AKR1C3 (0.37) | PTGS2PTGS1CYP11B1CYP11B2RXRA | |
| SCHEMBL2741546 | 0.85 | CYP11B1 (0.34) | MAPTCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862886-B2 | Compound, liquid crystal composition including the same, and liquid crystal display device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-01-09 | — | — | US | disclosed |
| US-20160369167-A1 | COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME, AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-12-22 | — | — | US | disclosed |
| US-20160369167-A1 | COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME, AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160369167-A1 | COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME, AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME | SCO2, NCAPD3, OCIAD2 | PTGS2 4053/4885PTGS1 4355/4885KDM4E 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.